Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Formation of PetroLiance LLC via merger of two oil companies
Represented PetroLiance LLC, an oil company, which was formed upon the closing of a multi-a multimillion dollar financing and the merger of Southern more
Sale of assets of Dan River, Inc.
The firm represented Dan River, Inc., a Virginia-based textile manufacturer, in the $19 million sale of its assets. more
Faulkner v. National Geographic
As lead amici counsel for more than two dozen academic associations (including the American Association for the Advancement of Science), more
Cooper v. Sony Music Entertainment Inc., et al.
Defended Sony Music Entertainment Inc., So So Def Productions and other defendants in a series of lawsuits asserting copyright infringement and other more